Anxiety disorders, subsyndromic depressive episodes, and major depressive episodes: Do they differ on their impact on the quality of life of patients with epilepsy?

Epilepsia ◽  
2010 ◽  
Vol 51 (7) ◽  
pp. 1152-1158 ◽  
Author(s):  
Andres M. Kanner ◽  
John J. Barry ◽  
Frank Gilliam ◽  
Bruce Hermann ◽  
Kimford J. Meador
Keyword(s):  
Quality Of Life ◽  
Anxiety Disorders ◽  
Major Depressive ◽  
Patients With Epilepsy ◽  
Major Depressive Episodes ◽  
Depressive Episodes

scholarly journals ASSESSMENT OF DEPRESSION AND ANXIETY IN NEUROLOGICAL DISORDER PATIENTS AND THEIR RELATIONSHIP WITH QUALITY OF LIFE

2021 ◽  
Vol 21 (2) ◽  
pp. 112-123
Author(s):  
Priscilla Das ◽  
Nyi Nyi Naing ◽  
Nadiah Wan-Arfah ◽  
KON Noorjan ◽  
Yee Cheng Kueh ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Major Depressive Disorder ◽  
Panic Disorder ◽  
Depressive Disorder ◽  
Anxiety Disorders ◽  
Neurological Disorder ◽  
Life Questionnaire ◽  
Major Depressive ◽  
Compulsive Disorder

Objectives: To assess the association between major depressive disorder, anxiety disorders and the quality of life of neurological disorder (brain tumour/brain disorder) patients. Methods: This study was conducted at Kuala Lumpur Hospital, Malaysia, a tertiary referral centre hospital for neurological disorder patients. The cross-sectional study design was applied. The Mini-International Neuropsychiatric Interview and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire were used in the study. Results: A total of 100 neurological disorder patients were included in the study. The study found that the Major depressive disorder correlated with almost all domains of the quality of life, except the nausea and vomiting scores. Logistic regression showed that emotional functioning and pain were related to major depressive disorder. Different anxiety disorders also correlated with quality of life in specific domains. The leading anxiety disorders that associated mostly with quality of life scales were post traumatic stress disorder, panic disorder lifetime and current, panic disorder with agoraphobia, obsessive compulsive disorder, anxiety disorder and with agoraphobia current and social phobia current (p < 0.05). Conclusions: There is a significant relationship between psychiatric disorders and quality of life neurological disorder patients. Therefore treatment along with psychiatric intervention should be implemented to improve the overall curability of the neurological disorder patients.

scholarly journals The National Population Health Survey’s assessment of depression risk factor associations: a simulation study assessing vulnerability to bias

2012 ◽  
Vol 32 (2) ◽  
pp. 70-75
Author(s):  
S.B. Patten
Keyword(s):  
Risk Factor ◽  
Population Health ◽  
Major Depressive ◽  
National Population ◽  
Depression Risk ◽  
Hazard Ratios ◽  
Substantial Bias ◽  
Major Depressive Episodes ◽  
Depressive Episodes

Background In Canada, the major source of longitudinal information on major depression epidemiology has been the National Population Health Survey (NPHS). However, the timing of NPHS interviews may raise concerns about the quality of its estimates. Specifically, the NPHS interview assesses major depressive episodes (MDE) in the year before an interview, whereas the interviews are conducted 2 years apart. The objective of this study was to determine whether this aspect of the NPHS can be expected to introduce bias into longitudinal estimates of risk factor associations. Methods A simulation model was used to represent the underlying epidemiology and the expected results of a study adopting the NPHS approach to assessment of MDE. The model was used to explore the extent of the resulting distortion of estimates across a range of underlying hazard ratios. Results The simulations indicated that the timing and coverage of depression interviews in the NPHS would not introduce substantial bias. The model suggested that incidence would be underestimated as a result of episodes being missed, but that this would not substantially distort estimates of association. Conclusion The timing of interviews in the NPHS is not expected to cause biased relative risk estimates. NPHS estimates may, of course, be influenced by other sources of bias.

Features and methods of assessing health-related quality of life and cognitive functions in patients with glial tumors

2020 ◽  
pp. 47-56
Author(s):  
Vera Arsenyeva ◽  
Boris Martynov ◽  
Gennadiy Bulyshchenko ◽  
Dmitriy Svistov ◽  
Boris Gaydar ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cognitive Functions ◽  
Well Being ◽  
Health Related Quality ◽  
Number Of Patients ◽  
Related Quality ◽  
Health Related ◽  
Eortc Qlq ◽  
Patients With Epilepsy

Gliomas make up about 8 cases per 100,000 population and the number of patients with this disease is only increasing. There can be not only various types of neurological deficits among the symptoms, but also personal and emotional changes, that seriously affects the quality of life. The modern model of health care includes not only recovery of the patient’s physical functions, but also his or her psychosocial well-being. In particular, the assessment and study of the characteristics of health-related quality of life, as well as cognitive functions in patients with gliomas, is increasingly recognized as an important criterion when considering the effectiveness of treatment. To date, the features of health related quality of life and cognitive functions of patients with epilepsy and acute cerebral circulation disorders have been studied sufficiently, and, as a result, techniques have been developed that accurately assess the QOL and CF in patients with these diseases. These are QOLIE-31 and QOLIE-AD-48 questionnaires for patients with epilepsy. This is the National Institutes of Health Stroke Scale (NIHSS), Orgogozo stroke scale (OSS), World Federation of Neurological Surgeons (WFNS) scale for the clinical assessment of subarachnoid hemorrhage (SAH) for patients with acute cerebrovascular accident. At the same time, there are no generally accepted methods for assessing quality of life and neurocognitive functions that are sensitive to changes in the condition of patients with gliomas in the early postoperative period by the time of discharge from the hospital. As a result, there is no systematic information on the dynamics of the quality of life of such patients, their neurocognitive functioning. The purpose of this article was to study the literature on QOL and CF in patients affected by neurological and neurosurgical disorders for the further selection of optimal methods for assessing dynamics of the condition of patients with glial brain tumors before and after surgery. At the moment, such requirements are only partially met by the EORTC QLQ-C30 questionnaire and its application EORTC QLQ-BN20.

scholarly journals Duloxetine versus ‘active’ placebo, placebo or no intervention for major depressive disorder; a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis

2021 ◽  
Vol 10 (1) ◽  
Author(s):  
Faiza Siddiqui ◽  
Marija Barbateskovic ◽  
Sophie Juul ◽  
Kiran Kumar Katakam ◽  
Klaus Munkholm ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Systematic Review ◽  
Sequential Analysis ◽  
Citation Index ◽  
Trial Sequential Analysis ◽  
Random Errors ◽  
Major Depressive ◽  
Serious Adverse Events ◽  
Meta Analyses

Abstract Background Major depression significantly impairs quality of life, increases the risk of suicide, and poses tremendous economic burden on individuals and societies. Duloxetine, a serotonin norepinephrine reuptake inhibitor, is a widely prescribed antidepressant. The effects of duloxetine have, however, not been sufficiently assessed in earlier systematic reviews and meta-analyses. Methods/design A systematic review will be performed including randomised clinical trials comparing duloxetine with ‘active’ placebo, placebo or no intervention for adults with major depressive disorder. Bias domains will be assessed, an eight-step procedure will be used to assess if the thresholds for clinical significance are crossed. We will conduct meta-analyses. Trial sequential analysis will be conducted to control random errors, and the certainty of the evidence will be assessed using GRADE. To identify relevant trials, we will search Cochrane Central Register of Controlled Trials, Medical Literature Analysis and Retrieval System Online, Excerpta Medica database, PsycINFO, Science Citation Index Expanded, Social Sciences Citation Index, Conference Proceedings Citation Index—Science and Conference Proceedings Citation Index—Social Science & Humanities. We will also search Chinese databases and Google Scholar. We will search all databases from their inception to the present. Two review authors will independently extract data and perform risk of bias assessment. Primary outcomes will be the difference in mean depression scores on Hamilton Depression Rating Scale between the intervention and control groups and serious adverse events. Secondary outcomes will be suicide, suicide-attempts, suicidal ideation, quality of life and non-serious adverse events. Discussion No former systematic review has systematically assessed the beneficial and harmful effects of duloxetine taking into account both the risks of random errors and the risks of systematic errors. Our review will help clinicians weigh the benefits of prescribing duloxetine against its adverse effects and make informed decisions. Systematic review registration PROSPERO 2016 CRD42016053931

Impacts on Quality of Life with Escitalopram Monotherapy and Aripiprazole Augmentation in Patients with Major Depressive Disorder: A CAN-BIND Report

2021 ◽  
Author(s):  
Emma Morton ◽  
Venkat Bhat ◽  
Peter Giacobbe ◽  
Wendy Lou ◽  
Erin E. Michalak ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Repeated Measures ◽  
Short Form ◽  
Treatment Phase ◽  
Major Depressive ◽  
Symptomatic Remission ◽  
Substantial Degree

Abstract Introduction Many individuals with major depressive disorder (MDD) do not respond to initial antidepressant monotherapy. Adjunctive aripiprazole is recommended for treatment non-response; however, the impacts on quality of life (QoL) for individuals who receive this second-line treatment strategy have not been described. Methods We evaluated secondary QoL outcomes in patients with MDD (n=179). After 8 weeks of escitalopram, non-responders (<50% decrease in clinician-rated depression) were treated with adjunctive aripiprazole for 8 weeks (n=97); responders continued escitalopram (n=82). A repeated-measures ANOVA evaluated change in Quality of Life Enjoyment and Satisfaction Short Form scores. QoL was described relative to normative benchmarks. Results Escitalopram responders experienced the most QoL improvements in the first treatment phase. For non-responders, QoL improved with a large effect during adjunctive aripiprazole treatment. At the endpoint, 47% of patients achieving symptomatic remission still had impaired QoL. Discussion Individuals who were treated with adjunctive aripiprazole after non-response to escitalopram experienced improved QoL, but a substantial degree of QoL impairment persisted. Since QoL deficits may predict MDD recurrence, attention to ways to support this outcome is required.

Sign in / Sign up

Export Citation Format

Share Document